Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes
- PMID: 26224769
- DOI: 10.1093/cid/civ427
Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes
Abstract
Background: The hollow fiber system model of tuberculosis (HFS-TB), in tandem with Monte Carlo experiments, represents a drug development tool (DDT) with the potential for use to develop tuberculosis treatment regimens. However, the predictive accuracy of the HFS-TB, or any other nonclinical DDT such as an animal model, has yet to be robustly evaluated.
Methods: To avoid hindsight bias, a literature search was performed to identify clinical studies published at least 6 months after HFS-TB experiments' quantitative predictions. Steps to minimize bias and for reporting systematic reviews were applied as outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Publications were scored for quality of evidence. Accuracy was calculated using the mean absolute percentage error, then summated with weighting assigned by sample size and quality-of-evidence score. Given the lack of a gold-standard tuberculosis DDT, the forecasting accuracy of a completely unreliable tool was also calculated from 1000 simulated experiments for a random or "total guesswork" model.
Results: The quantitative forecasting accuracy (95% confidence interval [CI]) for the "total guesswork" model was 15.6% (95% CI, 8.7%-22.5%); bias was -0.1% (95% CI, -2.5% to 2.2%). Twenty clinical studies were published after HFS-TB experiments predicted optimal drug exposures and doses, susceptibility breakpoints, and optimal combination regimens. Based on these clinical studies, the predictive accuracy of the HFS-TB was 94.4% (95% CI, 84.3%-99.9%), and bias was 1.8% (95% CI, -13.7% to 6.2%).
Conclusions: The HFS-TB model is highly accurate at forecasting optimal drug exposures, doses, and dosing schedules for use in the clinic.
Keywords: Monte Carlo experiments; drug development tool; hollow fiber system; predictive accuracy; tuberculosis.
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
Similar articles
-
d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal.Clin Infect Dis. 2018 Nov 28;67(suppl_3):S308-S316. doi: 10.1093/cid/ciy624. Clin Infect Dis. 2018. PMID: 30496460 Free PMC article.
-
Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S10-7. doi: 10.1093/cid/civ425. Clin Infect Dis. 2015. PMID: 26224767
-
Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm.Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S18-24. doi: 10.1093/cid/civ426. Clin Infect Dis. 2015. PMID: 26224768
-
Strategic Regulatory Evaluation and Endorsement of the Hollow Fiber Tuberculosis System as a Novel Drug Development Tool.Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S5-9. doi: 10.1093/cid/civ424. Clin Infect Dis. 2015. PMID: 26224771
-
Nonclinical models for antituberculosis drug development: a landscape analysis.J Infect Dis. 2015 Jun 15;211 Suppl 3:S83-95. doi: 10.1093/infdis/jiv183. J Infect Dis. 2015. PMID: 26009617 Review.
Cited by
-
A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies.EBioMedicine. 2016 Apr;6:126-138. doi: 10.1016/j.ebiom.2016.02.040. Epub 2016 Feb 27. EBioMedicine. 2016. PMID: 27211555 Free PMC article.
-
d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal.Clin Infect Dis. 2018 Nov 28;67(suppl_3):S308-S316. doi: 10.1093/cid/ciy624. Clin Infect Dis. 2018. PMID: 30496460 Free PMC article.
-
Pharmacodynamics of Piperacillin-Tazobactam/Amikacin Combination versus Meropenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow Fiber Infection Model.Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0016222. doi: 10.1128/aac.00162-22. Epub 2022 Aug 4. Antimicrob Agents Chemother. 2022. PMID: 35924928 Free PMC article.
-
Isoniazid urine spectrophotometry for prediction of serum pharmacokinetics in adults with TB.IJTLD Open. 2024 Feb;1(2):90-95. doi: 10.5588/ijtldopen.23.0361. IJTLD Open. 2024. PMID: 38655375 Free PMC article.
-
Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis.Sci Adv. 2017 Aug 30;3(8):e1701102. doi: 10.1126/sciadv.1701102. eCollection 2017 Aug. Sci Adv. 2017. PMID: 28875168 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous